Prelude Therapeutics Incorporated (PRLD)

Price & Market Data

Price: $4.22

Daily Change: -$0.11 / 2.61%

Daily Range: $4.16 - $4.53

Market Cap: $340,085,440

Daily Volume: 241,676

Performance Metrics

1 Week: 1.15%

1 Month: -6.01%

3 Months: 93.81%

6 Months: 172.0%

1 Year: 376.1%

YTD: 51.03%

About Prelude Therapeutics Incorporated (PRLD)

Comprehensive data for Prelude Therapeutics Incorporated (PRLD) is available. Current price is 4.22, with a daily change of -$0.11 / 2.61%. Market cap is 340,085,440. View detailed performance metrics for all periods, including YTD, 1-week, 1-month, 3-month, 6-month, and 1-year returns.

Company Details

Employees: 79

Sector: Health technology

Industry: Biotechnology

Country: United States

Details

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

Selected stocks

Borr Drilling Limited (BORR)

iHeartMedia, Inc. (IHRT)

Helport AI Limited (HPAI)

Galiano Gold Inc. (GAU)

Adial Pharmaceuticals, Inc (ADIL)